Aprea Therapeutics, Inc.
APRE
$1.10
$0.076.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -98.48% | -27.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -98.48% | -27.32% | |||
| Cost of Revenue | -14.29% | -22.99% | |||
| Gross Profit | 8.75% | 22.69% | |||
| SG&A Expenses | -7.12% | -9.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.03% | -17.47% | |||
| Operating Income | 7.98% | 17.08% | |||
| Income Before Tax | 8.23% | 17.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.23% | 17.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.23% | 17.64% | |||
| EBIT | 7.98% | 17.08% | |||
| EBITDA | 7.99% | 17.10% | |||
| EPS Basic | 12.40% | 18.85% | |||
| Normalized Basic EPS | 12.41% | 18.85% | |||
| EPS Diluted | 12.40% | 18.85% | |||
| Normalized Diluted EPS | 12.41% | 18.85% | |||
| Average Basic Shares Outstanding | 4.76% | 1.49% | |||
| Average Diluted Shares Outstanding | 4.76% | 1.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||